July 23, 2014 8:50 PM ET


Company Overview of Aegis Therapeutics, LLC

Company Overview

Aegis Therapeutics, LLC operates as a drug delivery technology company commercializing drug delivery and drug formulation technologies. It offers Intravail drug delivery technology that enables the non-invasive delivery of a broad range of protein, peptide, and non-peptide macromolecular therapeutics; ProTek technology for peptide or protein therapeutics that maintain the structural integrity and physiological activity of various protein and peptide drugs; and Aegis Hydrogels that are absorption-enhancing self-assembling aqueous hydrogels for transdermal drug delivery or transmucosal applications serving simultaneously as delivery vehicle and absorption enhancer. The company was founded in 2...

16870 West Bernardo Drive

Suite 390

San Diego, CA 92127

United States

Founded in 2003





Key Executives for Aegis Therapeutics, LLC

Chief Executive Officer and Director
Executive Chairman
Age: 72
Chief Business Officer and Director
Member of Advisory Board
Compensation as of Fiscal Year 2014.

Aegis Therapeutics, LLC Key Developments

Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM

Aegis Therapeutics, LLC Presents at BIO International Convention, Jun-25-2014 04:15 PM. Venue: San Diego Convention Center, San Diego, California, United States.

Aegis Intravail(R) Technology Enhances Oral Bioavailability of Tableted OTC Drugs

Aegis Therapeutics LLC's Intravail(R) technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral bioavailability by more than 50%. This is the first application of Intravail(R) in a solid dosage form. The Intravail formulation is compatible with current tableting processes employed for OTC and prescription drugs and does not alter tablet size or appearance. Previously published studies have shown that Intravail(R) alkylsaccharide excipients increase oral bioavailability of a number of peptide and nonpeptide drugs in preclinical studies. Examples include exenatide, octreotide, desmopressin, heparin, sumatriptan and a 7kDa antisense (nucleotide analog) drug. In these latter applications, Intravail was incorporated into aqueous formulations or fast dissolve or chewable formats. The extension of the use of Intravail(R) into solid dosage forms represents a significant expansion of the broad applicability of this technology. Intravail(R) excipients are equally soluble in pharmaceutically accepted oils thus permitting use as oral absorption enhancers in gel caps as well. Sixteen US and foreign patents have issued to date and Notice of Allowance has been received on two additional patents that will issue shortly covering various aspects of the Intravail(R)/ProTek(R) alkylsaccharide-based technologies. More than 50 additional patent applications are currently pending. Aegis licenses its Intravail(R) drug delivery and ProTek(R) protein stabilization technologies to biopharmaceutical companies worldwide and is now seeking licensees for the application of Intravail to a broad range of over-the-counter drugs where increased bioavailability or more rapid onset of action would offer improved performance and significant market differentiation in a crowded field.

Similar Private Companies By Industry

Company Name Region
Hadron Systems, Inc. United States
Navisonics, Inc. United States
Eiger BioPharmaceuticals, Inc. United States
MetaMorphix Inc. United States
Origen, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aegis Therapeutics, LLC, please visit www.aegisthera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.